4/18/2015 6:38 AM IPN.PA 45.45 € (+1.68 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 4/16/2015

    Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer

    Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer
  • 4/8/2015

    Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors

    Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors
  • 4/1/2015

    Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement

    Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement
  • 4/1/2015

    Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence

    Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence
  • 3/31/2015

    The Ipsen Group publishes its 2014 Registration document

    The Ipsen Group publishes its 2014 Registration document
  • 3/4/2015

    Precisions concerning the resupply of Increlex® in the U.S.

    Precisions concerning the resupply of Increlex® in the U.S.
  • 3/3/2015

    Ipsen’s 2014 results and 2015 financial objectives

    Ipsen’s 2014 results and 2015 financial objectives
  • 3/2/2015

    Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

    Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015
  • 3/2/2015

    Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer

    Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer
  • 2/24/2015

    Ipsen enters into option agreement to acquire Canbex Therapeutics

    Ipsen enters into option agreement to acquire Canbex Therapeutics